Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder

被引:221
|
作者
Robinson, DG [1 ]
Woerner, MG
Alvir, JMJ
Bilder, RM
Hinrichsen, GA
Lieberman, JA
机构
[1] Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Dept Psychiat Res, Glen Oaks, NY 11004 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[4] Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Dept Psychol Serv, Glen Oaks, NY 11004 USA
[5] Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Div Geriatr Psychiat, Glen Oaks, NY 11004 USA
[6] Univ N Carolina, Chapel Hill, NC 27515 USA
关键词
antipsychotic agents; cognition; neuropsychological tests; patient compliance; schizophrenia;
D O I
10.1016/S0920-9964(01)00312-7
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Enhancing medication adherence early in the course of schizophrenia and schizoaffective disorder may substantially improve long-term course. Although extensively studied in multi-episode patients, little data exist on medication adherence by first-episode patients. Method: Medication adherence was assessed during the first year of treatment and following recovery from the first relapse in patients treated by a standardized medication algorithm. Results: During the first year of treatment, patients with poorer premorbid cognitive functioning were more likely to stop antipsychotics (t = -2.54, df= 75, p = 0.01). Parkinsonian side effects increased the likelihood (hazard ratio=41.22; 95% CI= 2.30, 737.89; p=0.01), and better executive function decreased the likelihood (hazard ratio = 0.40; 95% Cl = 0.18, 0.88; p = 0.02) that patients discontinued maintenance medication after a first relapse. Conclusion: Interventions to ameliorate cognitive deficits and Parkinsonian side effects may enhance treatment adherence. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 50 条
  • [41] Shape differences in the corpus callosum in first-episode schizophrenia and first-episode psychotic affective disorder
    Frumin, M
    Golland, P
    Kikinis, R
    Hirayasu, Y
    Salisbury, DF
    Hennen, J
    Dickey, CC
    Anderson, M
    Jolesz, FA
    Grimson, WEL
    McCarley, RW
    Shenton, ME
    AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (05): : 866 - 868
  • [42] Specific executive dysfunction in patients with first-episode medication-naive schizophrenia
    Chan, RCK
    Chen, EYH
    Law, CW
    SCHIZOPHRENIA RESEARCH, 2006, 82 (01) : 51 - 64
  • [43] Comparative analysis of the neurocognitive profile of patients with a first episode of paranoid schizophrenia and schizoaffective disorder
    Zaytseva, Y.
    Gurovich, I. Y.
    Sarkisyan, G.
    Sarkisyan, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S348 - S348
  • [44] EEG correlates of a mental arithmetic task in patients with first episode schizophrenia and schizoaffective disorder
    Garakh, Zhanna
    Zaytseva, Yuliya
    Kapranova, Alexandra
    Fiala, Ondrej
    Horacek, Jiri
    Shmukler, Alexander
    Gurovich, Isaac Ya.
    Strelets, Valeria B.
    CLINICAL NEUROPHYSIOLOGY, 2015, 126 (11) : 2090 - 2098
  • [45] Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial
    Whicher, Clare Alexandra
    Price, Hermione Clare
    Phiri, Peter
    Rathod, Shanaya
    Barnard-Kelly, Katharine
    Reidy, Claire
    Thorne, Kerensa
    Asher, Carolyn
    Peveler, Robert
    McCarthy, Joanne
    Holt, Richard Ian Gregory
    TRIALS, 2019, 20 (01)
  • [46] Cognitive functioning in first-episode schizophrenia and bipolar disorder
    Murphy, PT
    Burke, T
    McTigue, O
    Kamali, M
    Clarke, M
    Larkin, C
    O'Callaghan, E
    Lane, A
    SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 267 - 268
  • [47] Antipsychotic Medication Adherence in Patients with Schizophrenia or Schizoaffective Disorder
    Reutfors, Johan
    Brandt, Lena
    Stephansson, Olof
    Kieler, Helle
    Andersen, Morten
    Boden, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 437 - 438
  • [48] Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial
    Holt, Richard I. G.
    Gossage-Worrall, Rebecca
    Hind, Daniel
    Bradburn, Michael J.
    McCrone, Paul
    Morris, Tiyi
    Edwardson, Charlotte
    Barnard, Katharine
    Carey, Marian E.
    Davies, Melanie J.
    Dickens, Chris M.
    Doherty, Yvonne
    Etherington, Angela
    French, Paul
    Gaughran, Fiona
    Greenwood, Kathryn E.
    Kalidindi, Sridevi
    Khunti, Kamlesh
    Laugharne, Richard
    Pendlebury, John
    Rathod, Shanaya
    Saxon, David
    Shiers, David
    Siddiqi, Najma
    Swaby, Elizabeth A.
    Waller, Glenn
    Wright, Stephen
    Holt, Richard I. G.
    Barnard, Katharine
    Gossage-Worrall, Rebecca
    Bradburn, Mike
    Hind, Daniel
    Saxon, David
    Swaby, Lizzie
    French, Paul
    Pendlebury, John
    Wright, Stephen
    Waller, Glenn
    McCrone, Paul
    Morris, Tiyi
    Edwardson, Charlotte
    Khunti, Kamlesh
    Davies, Melanie
    Carey, Marian
    Doherty, Yvonne
    Northern, Alison
    Barnett, Janette
    Laugharne, Richard
    Dickens, Chris
    Greenwood, Kathryn
    BRITISH JOURNAL OF PSYCHIATRY, 2019, 214 (02) : 63 - 73
  • [49] Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial
    Clare Alexandra Whicher
    Hermione Clare Price
    Peter Phiri
    Shanaya Rathod
    Katharine Barnard-Kelly
    Claire Reidy
    Kerensa Thorne
    Carolyn Asher
    Robert Peveler
    Joanne McCarthy
    Richard Ian Gregory Holt
    Trials, 20
  • [50] Symptomatic and functional recovery from a first episode of schizophrenia or Schizoaffective disorder
    Robinson, DG
    Woerner, MG
    McMeniman, M
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03): : 473 - 479